Ascendis Pharma A/S Stock Forecast, Price & News

-0.77 (-0.56 %)
(As of 06/18/2021 02:52 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5,267 shs
Average Volume210,958 shs
Market Capitalization$7.39 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Ascendis Pharma A/S logo

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.04 out of 5 stars

Medical Sector

73rd out of 2,100 stocks

Pharmaceutical Preparations Industry

31st out of 831 stocks

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

Is Ascendis Pharma A/S a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ascendis Pharma A/S stock.
View analyst ratings for Ascendis Pharma A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Ascendis Pharma A/S?

Wall Street analysts have given Ascendis Pharma A/S a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ascendis Pharma A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 26th 2021.
View our earnings forecast for Ascendis Pharma A/S

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings results on Wednesday, May, 26th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($2.06) by $0.89. The biotechnology company earned $0.90 million during the quarter, compared to the consensus estimate of $1.94 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 54.80% and a negative net margin of 7,700.88%.
View Ascendis Pharma A/S's earnings history

How has Ascendis Pharma A/S's stock price been impacted by COVID-19 (Coronavirus)?

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ASND shares have increased by 16.5% and is now trading at $138.10.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ASND?

10 brokers have issued twelve-month target prices for Ascendis Pharma A/S's stock. Their forecasts range from $178.00 to $216.00. On average, they expect Ascendis Pharma A/S's share price to reach $192.43 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price.
View analysts' price targets for Ascendis Pharma A/S
or view top-rated stocks among Wall Street analysts.

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the following people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 50)
  • Mr. Jan Moller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 61)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 47)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 52)
  • Ms. Lotte Sonderbjerg, Chief Admin. Officer & Sr. VP (Age 60)
  • Mr. Ami Knoefler, Head of Global Communications
  • Mr. Flemming Steen Jensen, Sr. VP of Product Supply (Age 60)
  • Dr. Kennett Sprogoe, Sr. VP and Head of Innovation & Research (Age 42)
  • Dr. Juha Punnonen M.D., Ph.D., Sr. VP & Head of Oncology (Age 55)
  • Dr. Jens Sigurd Okkels, Sr. VP of Product Devel. (Age 60)

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (11.93%), Artisan Partners Limited Partnership (11.25%), Price T Rowe Associates Inc. MD (9.44%), Janus Henderson Group PLC (5.89%), Vivo Capital LLC (3.10%) and Lone Pine Capital LLC (2.67%).

Which major investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Vivo Capital LLC, Putnam Investments LLC, Polar Capital Holdings Plc, Morgan Stanley, Ameriprise Financial Inc., TD Asset Management Inc., and Schonfeld Strategic Advisors LLC.

Which major investors are buying Ascendis Pharma A/S stock?

ASND stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Lone Pine Capital LLC, Artisan Partners Limited Partnership, Brown Advisory Inc., Orbimed Advisors LLC, Thrivent Financial for Lutherans, Janus Henderson Group PLC, and Eversept Partners LP.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $138.10.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S has a market capitalization of $7.43 billion and generates $7.94 million in revenue each year. The biotechnology company earns $-478,570,000.00 in net income (profit) each year or ($9.46) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

Ascendis Pharma A/S employs 482 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is

Where are Ascendis Pharma A/S's headquarters?

Ascendis Pharma A/S is headquartered at TUBORG BOULEVARD 12, HELLERUP G7, DK-2900.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.